Emergent BioSolutions Stock Forecast, Price & News

-0.96 (-1.54 %)
(As of 07/27/2021 11:02 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2,736 shs
Average Volume507,838 shs
Market Capitalization$3.29 billion
P/E Ratio8.55
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive EBS News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

Emergent BioSolutions logo

About Emergent BioSolutions

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.77 out of 5 stars

Medical Sector

208th out of 2,218 stocks

Pharmaceutical Preparations Industry

99th out of 869 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Emergent BioSolutions (NYSE:EBS) Frequently Asked Questions

Is Emergent BioSolutions a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Emergent BioSolutions stock.
View analyst ratings for Emergent BioSolutions
or view top-rated stocks.

What stocks does MarketBeat like better than Emergent BioSolutions?

Wall Street analysts have given Emergent BioSolutions a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Emergent BioSolutions wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Emergent BioSolutions?

Emergent BioSolutions saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 3,580,000 shares, an increase of 20.5% from the June 15th total of 2,970,000 shares. Based on an average daily volume of 790,700 shares, the short-interest ratio is currently 4.5 days. Approximately 7.4% of the company's stock are short sold.
View Emergent BioSolutions' Short Interest

When is Emergent BioSolutions' next earnings date?

Emergent BioSolutions is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Emergent BioSolutions

How can I listen to Emergent BioSolutions' earnings call?

Emergent BioSolutions will be holding an earnings conference call on Thursday, July 29th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) announced its quarterly earnings results on Wednesday, April, 28th. The biopharmaceutical company reported $1.53 EPS for the quarter, topping analysts' consensus estimates of $0.97 by $0.56. The biopharmaceutical company had revenue of $343 million for the quarter, compared to the consensus estimate of $368.62 million. Emergent BioSolutions had a net margin of 22.70% and a trailing twelve-month return on equity of 37.42%.
View Emergent BioSolutions' earnings history

How has Emergent BioSolutions' stock been impacted by Coronavirus (COVID-19)?

Emergent BioSolutions' stock was trading at $53.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EBS shares have increased by 15.8% and is now trading at $61.41.
View which stocks have been most impacted by COVID-19

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions updated its second quarter 2021 earnings guidance on Tuesday, May, 11th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $370 million-$430 million, compared to the consensus revenue estimate of $502.27 million.

What price target have analysts set for EBS?

6 equities research analysts have issued twelve-month price targets for Emergent BioSolutions' stock. Their forecasts range from $64.00 to $120.00. On average, they anticipate Emergent BioSolutions' stock price to reach $96.50 in the next year. This suggests a possible upside of 57.1% from the stock's current price.
View analysts' price targets for Emergent BioSolutions
or view top-rated stocks among Wall Street analysts.

Who are Emergent BioSolutions' key executives?

Emergent BioSolutions' management team includes the following people:
  • Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 63, Pay $1.2M)
  • Mr. Robert G. Kramer, CEO, Pres & Exec. Director (Age 64, Pay $2.13M)
  • Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 57, Pay $1.02M)
  • Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 48, Pay $983.57k)
  • Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 50, Pay $1M)
  • Mr. Sean M. Kirk, Exec. VP of Manufacturing & Technical Operations (Age 46)
  • Mr. Howard Anderson, Sr. VP & Chief Information Officer
  • Mr. Robert G. Burrows, VP of Investor Relations
  • Ms. Lynn Kieffer, VP of Corp. Communications
  • Ms. Nina DeLorenzo, Sr. VP of Global Communications & Public Affairs

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions CEO Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among Emergent BioSolutions' employees.

Who are some of Emergent BioSolutions' key competitors?

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), salesforce.com (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Square (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (0.64%), Oregon Public Employees Retirement Fund (0.03%), New Mexico Educational Retirement Board (0.02%) and Integrated Investment Consultants LLC (0.01%). Company insiders that own Emergent BioSolutions stock include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends for Emergent BioSolutions

Which major investors are selling Emergent BioSolutions stock?

EBS stock was sold by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P.. Company insiders that have sold Emergent BioSolutions company stock in the last year include Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Robert Kramer, Sue Bailey, and Zsolt Harsanyi.
View insider buying and selling activity for Emergent BioSolutions
or view top insider-selling stocks.

Which major investors are buying Emergent BioSolutions stock?

EBS stock was acquired by a variety of institutional investors in the last quarter, including Integrated Investment Consultants LLC, New Mexico Educational Retirement Board, and Oregon Public Employees Retirement Fund.
View insider buying and selling activity for Emergent BioSolutions
or or view top insider-buying stocks.

How do I buy shares of Emergent BioSolutions?

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $61.41.

How much money does Emergent BioSolutions make?

Emergent BioSolutions has a market capitalization of $3.29 billion and generates $1.56 billion in revenue each year. The biopharmaceutical company earns $305.10 million in net income (profit) each year or $7.88 on an earnings per share basis.

How many employees does Emergent BioSolutions have?

Emergent BioSolutions employs 2,200 workers across the globe.

What is Emergent BioSolutions' official website?

The official website for Emergent BioSolutions is www.emergentbiosolutions.com.

Where are Emergent BioSolutions' headquarters?

Emergent BioSolutions is headquartered at 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]

This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.